Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Drug Name | MEDI5083 |
Trade Name | |
Synonyms | MEDI 5083|MEDI-5083 |
Drug Descriptions |
MEDI5083 is a fusion protein consisting of CD40LG (CD40L) ligand and an immunoglobulin (Ig) Fc fragment, which activates TNFRSF5 (CD40) to stimulate proliferation of T-cells and enhance an anti-tumor response (AACR; Cancer Res 2018;78(13 Suppl):Abstract nr CT126). |
DrugClasses | |
CAS Registry Number | NA |
NCIT ID | C148416 |
Therapy Name | Drugs | Efficacy Evidence | Clinical Trials |
---|---|---|---|
Durvalumab + MEDI5083 | Durvalumab MEDI5083 | 0 | 1 |
MEDI5083 | MEDI5083 | 0 | 1 |